




Instance: composition-en-96958c1c1275e460bebf23cdf143ad79
InstanceOf: CompositionUvEpi
Title: "Composition for lysodren Package Leaflet"
Description:  "Composition for lysodren Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/04/273/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp96958c1c1275e460bebf23cdf143ad79)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lysodren"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Lysodren is and what it is used for </li>
<li>What you need to know before you take Lysodren </li>
<li>How to take Lysodren </li>
<li>Possible side effects </li>
<li>How to store Lysodren </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lysodren is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lysodren is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lysodren is an antitumoral medicine. </p>
<p>This medicine is used for the treatment of symptoms of advanced non operable, metastatic or recurrent 
malignant tumours of the adrenal glands. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lysodren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lysodren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Lysodren 
- if you are allergic to mitotane or any of the other ingredients of this medicine (listed in 
section 6). 
- if you are breast-feeding. You must not breast-feed while taking Lysodren. 
- if you are being treated with medicines containing spironolactone (see "Other medicines and 
Lysodren"). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Lysodren. 
You should tell your doctor if any of the following applies to you:</p>
<ul>
<li>if you have an injury (shock, severe trauma), an infection or if you have any illness while you 
are taking Lysodren. Tell your doctor immediately, who may decide to temporarily stop 
treatment. </li>
<li>if you have liver problems: Tell your doctor if you develop any of the following signs and 
symptoms of liver problems during Lysodren treatment: itching, yellow eyes or skin, dark urine, 
and pain or discomfort in the right upper stomach area. Your doctor should do blood tests to 
check your liver function before and during treatment with Lysodren, and as clinically 
indicated. </li>
<li>
<p>if you have severe kidney problems. </p>
</li>
<li>
<p>if you are using any medicines mentioned below (see "Other medicines and Lysodren"). </p>
</li>
<li>if you have gynaecological problems such as bleeding and/ or pelvic pain. </li>
</ul>
<p>This medicine should not be handled by persons other than the patient and his/her caregivers, and 
especially not by pregnant women. Caregivers should wear disposable gloves when handling the 
tablets. </p>
<p>Your doctor may prescribe you some hormonal treatment (steroids) while you are taking Lysodren. </p>
<p>Always keep with you the Lysodren Patient Card included at the end of this leaflet. </p>
<p>Other medicines and Lysodren 
Please tell your doctor or pharmacist if you are using or have recently used any other medicines, 
including medicines obtained without a prescription. </p>
<p>You must not use Lysodren with medicines containing spironolactone, often used as a diuretic for 
heart, liver or kidney diseases. </p>
<p>Lysodren may interfere with several medicines. Therefore, you should tell your doctor if you are using 
medicines containing any of the following active substances:</p>
<ul>
<li>warfarin or other anticoagulants (blood thinners), used to prevent blood clots. The dose of your 
anticoagulant may need adjustment. </li>
<li>antiepileptics </li>
<li>rifabutin or rifampicin, used to treat tuberculosis </li>
<li>griseofulvin, used in the treatment of fungal infections </li>
<li>herbal preparations containing St. John s wort (Hypericum perforatum) </li>
<li>Sunitinib, etoposide: to treat cancer </li>
</ul>
<p>Lysodren with food and drink 
Lysodren should preferably be taken during meals containing fat-rich food such as milk, chocolate, 
oil. </p>
<p>Pregnancy, breast-feeding and fertility 
Lysodren may harm the foetus. If you are pregnant or planning to become pregnant, tell your doctor. 
If you may become pregnant, you should use an effective contraception during treatment with 
Lysodren and even after stopping it, ask your doctor for advice.  </p>
<p>You must not breast-feed while taking Lysodren and even after stopping it. Ask your doctor for 
advice. </p>
<p>Driving and using machines 
Lysodren has a major influence on your ability to drive and use machines. Ask your doctor for advice. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lysodren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lysodren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>Dose and schedule 
The usual starting dose for adults is 2 to 3 g (4 to 6 tablets) per day. 
Your doctor may start treatment at higher doses such as 4 to 6 g (8 to 12 tablets). </p>
<p>In order to find the optimal dose for you, your doctor will monitor regularly the levels of Lysodren in 
your blood. Your doctor may decide to stop treatment with Lysodren temporarily or to lower the dose 
if you experience certain side effects. </p>
<p>Use in children and adolescents<br />
The starting daily dose of Lysodren is 1.5 to 3.5 g/m2 body surface (this will be calculated by your 
doctor according to the weight and the size of the child). The experience in patients in this age group is 
very limited. </p>
<p>Method of administration 
You should swallow the tablets with a glass of water during meals containing fat-rich food. You can 
divide the total daily dose in two or three intakes. </p>
<p>If you take more Lysodren than you should 
Tell your doctor immediately if you have taken accidentally more Lysodren than you should or if a 
child has accidentally swallowed some. </p>
<p>If you forget to take Lysodren 
If you accidentally miss a dose, just take the next dose as scheduled. Do not take a double dose to 
make up for the forgotten one. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, Lysodren can cause side effects, although not everybody gets them. </p>
<p>Tell your doctor immediately if you experience any of the following side effects:</p>
<ul>
<li>Adrenal insufficiency: fatigue, abdominal pain, nausea, vomiting, diarrhoea, confusion </li>
<li>Anaemia: cutaneous pallor, muscular fatigability, feeling breathless, vertigo especially when 
standing up </li>
<li>Liver damage: yellowing of the skin and eyes, itching, nausea, diarrhoea, fatigue, dark coloured 
urine </li>
<li>Neurological disorders: movement and coordination disorders, abnormal sensations like pins 
and needles, memory loss, concentration difficulty, difficulty to talk, vertigo </li>
</ul>
<p>These symptoms may reveal complications for which specific medication could be appropriate. </p>
<p>Side effects may occur with certain frequencies, which are defined as follows:</p>
<ul>
<li>very common: may affect more than 1 in 10 people </li>
<li>common: may affect up to 1 in 10 people  </li>
<li>not known: frequency cannot be estimated from the available data </li>
</ul>
<p>Very common side effects 
- vomiting, nausea (feeling sick), diarrhoea, belly pain 
- lack of appetite 
- abnormal sensations like pins and needles 
- movement and coordination disorders, vertigo, confusion 
- feeling sleepy, fatigue, muscle weakness (fatigue of muscle during effort) 
- inflammation (swelling, heat, pain) of mucosa, skin rash 
- blood disorders (bleeding time prolonged)<br />
- increase of cholesterol, triglycerides (fats) and liver enzymes (in blood tests) 
- decrease in white blood cells count<br />
- breast overdevelopment in men 
- adrenal insufficiency </p>
<p>Common side effects<br />
- dizziness, headache </p>
<ul>
<li>peripheral nervous system disorders (association of sensory disorders, muscular weakness and 
atrophy, decrease of tendon reflex and vasomotor symptoms such as hot flushes, sweat and 
sleep disorders) </li>
<li>mental impairment (such as memory loss, concentration difficulty) </li>
<li>movement disorder </li>
<li>decrease of red blood cells (anaemia, with symptoms such as skin pallor and fatigue), decrease 
in blood platelets (may make you more prone to bruising and bleeding) </li>
<li>hepatitis (auto-immune) (may cause yellowing of the skin and eyes, dark coloured urine) </li>
<li>difficulty of coordinating muscles </li>
</ul>
<p>Frequency Not Known 
- fever 
- general aching 
- flushing, high or low blood pressure, feeling of dizziness/vertigo when you suddenly stand up 
- increased production of saliva 
- eye disorders: visual impairment, vision blurred, double vision, distortion of images, complain 
of glare 
- fungal infection 
- liver damage (may cause yellowing of the skin and eyes, dark coloured urine) 
- decreased uric acid in blood tests<br />
- bladder inflammation with bleeding 
- presence of blood in urine, presence of proteins in urine 
- balance disorder 
- distortion of the sense of taste 
- impaired digestion 
- ovarian macrocysts (with symptoms such as pelvic pain, bleeding) 
- decreased androstenedione (precursor of sex hormones) in blood tests in females 
- decreased testosterone (sex hormone) in blood tests in females 
- sex hormone binding globulin (a protein which binds sex hormones) increased in blood tests 
- decreased free testosterone (sex hormone) in blood tests in males 
- hypogonadism in males (with symptoms such as breast overdevelopment, libido decreased, 
erectile dysfunction, fertility disorders) 
- allergic reactions, itching  </p>
<p>In children and adolescents, thyroid problems, neuro-psychological, growth retardation and one case 
of encephalopathy have been observed. In addition, some signs of hormonal changes (such as breast 
overdevelopment in males and vaginal bleeding and/or early breast development in females) have 
been observed. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lysodren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lysodren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Store in the original packaging. After opening: 1 year. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the bottle after EXP. </p>
<p>Any unused product or waste material should be disposed of in accordance with local requirements for 
cytotoxic medicines. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Lysodren contains 
- The active substance is mitotane. Each tablet contains 500 mg of mitotane. 
- The other ingredients are maize starch, microcrystalline cellulose (E 460), macrogol 3350 and 
silica colloidal anhydrous. </p>
<p>What Lysodren looks like and contents of the pack 
Lysodren tablets are white, biconvex, round and scored. 
Lysodren is available in plastic bottles of 100 tablets. </p>
<p>Marketing Authorisation Holder 
HRA Pharma Rare Diseases 
200 avenue de Paris 
92320 CHATILLON 
France </p>
<p>Manufacturer<br />
Latina Pharma S.p.A. 
Via Murillo, 7 
04013 Sermoneta (LT) 
Italy </p>
<p>or  </p>
<p>CENTRE SPECIALITES PHARMACEUTIQUES 
76-78, avenue du Midi 
63800 COURNON D AUVERGNE 
FRANCE  </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency (EMA) web 
site: http://www.emea.europa.eu/. There are also links to other websites about rare diseases and 
treatments. </p>
<p>This leaflet is available in all European languages on the EMA website. </p>
<p>LYSODREN   PATIENT   CARD </p>
<p>I am on Lysodren (mitotane) treatment </p>
<p>I am prone to acute adrenal insufficiency </p>
<p>In case I need emergency care,<br />
adequate precautionary measures 
should be taken </p>
<p>The name of my Doctor is: </p>
<p>.. 
Phone:  . </p>
<p>For information on the product, 
 please contact: 
 HRA Pharma Rare Diseases 
Tel: + 33 1 40 33 93 medinfo-rd@hra-pharma.com </p>         </div>"""      



Instance: composition-da-96958c1c1275e460bebf23cdf143ad79
InstanceOf: CompositionUvEpi
Title: "Composition for lysodren Package Leaflet"
Description:  "Composition for lysodren Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/04/273/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp96958c1c1275e460bebf23cdf143ad79)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lysodren"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Lysodren 
3. Sådan skal De tage Lysodren 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lysodren is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lysodren is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lysodren er et antitumormiddel. </p>
<p>Dette lægemiddel anvendes til behandling af symptomer på fremskredne ikke-operable, metastatiske 
eller tilbagevendende maligne tumorer i binyrerne.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lysodren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lysodren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Lysodren 
- hvis De er allergisk over for mitotan eller et af de øvrige indholdsstoffer i Lysodren (angivet i 
punkt 6). 
- hvis De ammer. De må ikke amme, mens De tager Lysodren. 
- hvis De bliver behandlet med lægemidler med spironolacton (se "Brug af andre lægemidler 
sammen med Lysodren"). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apoteketspersonalet, før De tager Lysodren. 
De skal fortælle lægen, hvis noget af følgende gælder for Dem:</p>
<ul>
<li>Hvis De kommer til skade (shock, alvorligt traume), får en infektion, eller hvis De bliver syg, 
mens De tager Lysodren. Fortæl det straks til Deres læge, som kan beslutte at stoppe Lysodren 
for en tid. </li>
<li>
<p>Hvis De har leverproblemer: Fortæl det til lægen, hvis De udvikler et af følgende tegn og 
symptomer på leverproblemer under behandling med Lysodren: kløe, gulfarvning af øjne eller 
hud, mørk urin og smerter eller ubehag øverst til højre i maveregionen. Lægen skal tage nogle 
blodprøver for at kontrollere Deres leverfunktion før og under behandling med Lysodren og 
desuden, hvis der er klinisk behov for det. </p>
</li>
<li>
<p>Hvis De har svære nyreproblemer. </p>
</li>
<li>Hvis De bruger lægemidler, der er nævnt herunder (Se "Brug af andre lægemidler sammen med 
Lysodren"). </li>
<li>Hvis De har underlivsproblemer som blødning og/eller smerter.  </li>
</ul>
<p>Dette lægemiddel bør ikke håndteres af andre personer end patienten og hans/hendes plejere. Dette 
gælder særligt gravide kvinder. Plejere bør bruge engangshandsker, når de håndterer tabletterne. </p>
<p>Deres læge kan ordinere hormonbehandling (steroider), når De tager Lysodren. </p>
<p>Hav altid det patientkort, der findes til sidst i denne indlægsseddel, på Dem. </p>
<p>Brug af andre lægemidler sammen med Lysodren 
Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger andre lægemidler, for nylig har brugt 
andre lægemidler eller planlægger at bruge andre lægemidler. Dette gælder også lægemidler, som ikke 
er købt på recept.  </p>
<p>De må ikke bruge Lysodren sammen med lægemidler, som indeholder spironolacton, der ofte bruges 
som et vanddrivende middel til hjerte-, lever- og nyresygdomme. </p>
<p>Lysodren kan påvirke adskillige lægemidler. De bør derfor informere Deres læge, hvis De bruger 
lægemidler, der indeholder et af følgende aktive stoffer:</p>
<ul>
<li>Warfarin eller andre antikoagulantia (blodfortyndende midler), der bruges til at forebygge 
blodpropper. Dosis af Deres blodfortyndende midler skal måske justeres. </li>
<li>Antiepileptika. </li>
<li>Rifabutin eller rifampicin, der bruges til behandling af tuberkulose. </li>
<li>Griseofulvin, der bruges til behandling af svampeinfektioner </li>
<li>Naturmedicin, der indeholder perikon (Hypericum perforatum). </li>
<li>Sunitinib, etoposid: til behandling af kræft </li>
</ul>
<p>Brug af Lysodren sammen med mad og drikke 
Lysodren bør fortrinsvis tages i forbindelse med måltider med madvarer med et højt indhold af fedt, 
såsom mælk, chokolade, olie. </p>
<p>Graviditet, amning og frugtbarhed 
Spørg Deres læge eller apotekspersonalet til råds, før De tager nogen form for lægemidler. </p>
<p>Lysodren kan skade fostret. Hvis De er gravid eller planlægger at blive gravid, skal De fortælle det til 
Deres læge. Hvis De har mulighed for at blive gravid, bør De anvende sikker kontraception under 
behandlingen med Lysodren, og når behandlingen er slut. Spørg Deres læge til råds. </p>
<p>De må ikke amme, mens De tager Lysodren og heller ikke efter, De er holdt op. Spørg Deres læge til 
råds. </p>
<p>Trafik- og arbejdssikkerhed 
Lysodren påvirker i væsentlig grad evnen til at føre og betjene maskiner. Spørg Deres læge til råds. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lysodren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lysodren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller på 
apotekspersonalet. </p>
<p>Den sædvanlige dosis er 
Den normale startdosis for en voksen er 2 til 3 g (4 til 6 tabletter) om dagen. 
Deres læge kan starte behandlingen med højere doser, som f.eks. 4 til 6 g (8 til 12 tabletter).  </p>
<p>For at finde den optimale dosis til Dem vil Deres læge regelmæssigt overvåge niveauet af Lysodren i </p>
<p>Deres blod. Deres læge kan beslutte at stoppe behandlingen med Lysodren for en tid eller at sænke 
dosis, hvis De oplever visse bivirkninger.  </p>
<p>Brug til børn og unge 
Den daglige startdosis Lysodren er 1,5 til 3,5 g/m² legemsoverflade (dette vil blive beregnet af Deres 
læge ud fra barnets vægt og størrelse). Erfaringen med patienter i denne aldersgruppe er meget 
begrænset. </p>
<p>Indgivelsesmåde 
De skal sluge tabletter med et glas vand i forbindelse med måltider med madvarer med et højt 
fedtindhold. Den totale daglige dosis kan fordeles på to eller tre doser. </p>
<p>Hvis De har taget for meget Lysodren 
Underret straks Deres læge, hvis De ved et uheld har taget flere Lysodren-tabletter, end De skulle, 
eller hvis et barn ved et uheld har slugt nogle. </p>
<p>Hvis De har glemt at tage Lysodren 
Hvis De ved et uheld springer en dosis over, så tag bare den næste dosis som planlagt. De må ikke tage 
en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>Fortæl det straks til Deres læge, hvis De oplever nogen af følgende bivirkninger:</p>
<ul>
<li>Nedsat funktion af binyrebarken: Træthed, mavesmerter, kvalme, opkastning, diarré og 
forvirring. </li>
<li>Anæmi: Bleghed, muskelsvaghed, stakåndethed, svimmelhed, især når De rejser Dem. </li>
<li>Leverskade: Gulfarvning af hud og øjne, kløe, kvalme, diarré, træthed, mørk urin </li>
<li>Neurologiske forstyrrelser: Bevægelses- og koordinationsforstyrrelser, unormale fornemmelser 
såsom sovende fornemmelse, hukommelsestab, koncentrationsbesvær, talebesvær, svimmelhed. </li>
</ul>
<p>Disse symptomer kan være tegn på komplikationer, som kan behandles med bestemte lægemidler. </p>
<p>Bivirkninger kan forekomme med visse hyppigheder, der defineres som følger:</p>
<ul>
<li>Meget almindelig: Kan forekomme flere end 1 ud af 10 personer. </li>
<li>Almindelig: Kan forekomme op til 1 ud af 10 personer. </li>
<li>Ikke kendt: Hyppigheden kan ikke estimeres ud fra forhåndenværende data. </li>
</ul>
<p>Meget almindelige bivirkninger 
- Opkastning, kvalme, diarré, mavesmerter. 
- Manglende appetit. 
- Unormale følelser, såsom sovende fornemmelse. 
- Bevægelses- og koordinationsforstyrrelser, svimmelhed, forstyrrelse. 
- Søvnighed, træthed, muskelsvaghed (muskeltræthed under anstrengelse). 
- Inflammation (hævelse, varme, smerter) i slimhinder, hududslæt. 
- Blødningsforstyrrelser (forlænget blødningstid). 
- Forhøjet kolesterol, triglycerider (fedtstoffer) og leverenzymer (i blodprøver). 
- Fald i antallet af hvide blodlegemer. 
- Udvikling af bryster hos mænd. 
- Nedsat funktion af binyrebarken. </p>
<p>Almindelige bivirkninger 
- Svimmelhed, hovedpine. </p>
<ul>
<li>Lidelser i det perifere nervesystem: Fornemmelse af føleforstyrrelser, muskelsvaghed og 
muskelsvind, nedsat senerefleks og kredsløbssymptomer, såsom hedeture, sved, og 
søvnforstyrrelser. </li>
<li>Mental svækkelse (såsom hukommelsestab, koncentrationsbesvær). </li>
<li>Bevægelsesforstyrrelser. </li>
<li>Fald i antallet af røde blodlegemer (anæmi, med symptomer såsom bleghed og træthed), fald i 
antallet af blodplader (gør Dem mere udsat for blå mærker og blødning). </li>
<li>Hepatitis (autoimmun, dvs. kroppens celler angriber sig selv) (kan forårsage gulfarvning af hud 
og øjne, mørk urin). </li>
<li>Koordinationsbesvær. </li>
</ul>
<p>Hyppighed ikke kendt 
- Feber. 
- Generaliseret ømhed. 
- Rødme, for højt eller lavt blodtryk, svimmelhed/vertigo (fornemmelse af at snurre rundt), når 
De rejser Dem pludseligt. 
- Øget spytproduktion. 
- Øjenlidelser: Synssvækkelse, sløret syn, dobbeltsyn, billedforvrængning, blænding. 
- Svampeinfektion. 
- Leverskade (kan forårsage gulfarvning af hud og øjne, mørk urin). 
- Nedsat urinsyre i blodprøver. 
- Blæreinflammation med blødninger. 
- Blod i urinen, protein i urinen. 
- Balanceproblem. 
- Smagsforstyrrelser. 
- Nedsat fordøjelse. 
- Cyster på æggestokkene (med symptomer som underlivssmerter og blødning). 
- Nedsat androstendion (forstadium til kønshormoner) i blodprøver hos kvinder. 
- Nedsat testosteron (kønshormon) i blodprøver hos kvinder. 
- Forhøjet kønshormonbindende globulin (protein, der binder kønshormoner) i blodprøver. 
- Nedsat frit testosteron (kønshormon) i blodprøver hos mænd. 
- Hypogonadisme hos mænd (med symptomer som udvikling af bryster, nedsat sexlyst, 
rejsningsproblemer, frugtbarhedsforstyrrelser). 
- Allergiske reaktioner, kløe. </p>
<p>Hos børn og unge er der blevet observeret thyroideaproblemer (problemer med skjoldbruskkirtlen), 
neuropsykologisk retardering, væksthæmning og et tilfælde af encefalopati (forstyrrelse af hjernens 
funktion). Derudover er der blevet observeret nogle tegn på hormonelle ændringer (såsom 
overudvikling af bryster hos mænd og vaginal blødning og/eller tidlig brystudvikling hos kvinder). </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V*. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lysodren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lysodren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Opbevares i den originale pakning. Efter åbning: 1 år. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken efter EXP. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer for 
cytotoksiske lægemidler. </p>
<p>Spørg apotekspersonalet, hvordan De skal bortskaffe lægemiddelrester. Af hensyn til miljøet må De 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lysodren indeholder:</p>
<ul>
<li>Aktivt stof: mitotan. Hver tablet indeholder 500 mg mitotan. </li>
<li>Øvrige indholdsstoffer: majsstivelse, mikrokrystallinsk cellulose (E460), macrogol 3350 og 
silica, kolloid, vandfri. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Lysodrentabletter er hvide, bikonvekse, runde tabletter med delekærv. 
Lysodren findes i plastflasker med 100 tabletter. </p>
<p>Indehaver af markedsføringstilladelsen 
HRA Pharma Rare Diseases 
200 avenue de Paris 
92320 CHATILLON 
Frankrig </p>
<p>Fremstiller 
Latina Pharma S.p.A. 
Via Murillo, 7 <br />
04013 Sermoneta (LT) 
Italien </p>
<p>eller </p>
<p>CENTRE SPECIALITES PHARMACEUTIQUES 
76-78, avenue du Midi 
63800 COURNON D’AUVERGNE 
FRANKRIG </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>De kan finde yderligere oplysninger om dette lægemiddel på Det europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. Der er også links til andre websteder om sjældne sygdomme, 
og om, hvordan de behandles. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside. </p>
<p>─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─  </p>
<p>LYSODREN-PATIENTKORT </p>
<p>Jeg er i behandling med Lysodren (mitotan)  </p>
<p>Jeg er disponeret for akut 
binyrebarkinsufficiens </p>
<p>I tilfælde af, at jeg har behov for akut hjælp,<br />
bør der tages forsigtighedsforanstaltninger </p>
<p>Min læges navn er: </p>
<p>……………………………………….. 
Tlf.: …………………………………. </p>
<p>For information om produktet, kontakt: 
 HRA Pharma Rare Diseases 
Tlf.: + 33 1 40 33 93 Medinfo-rd@hra-pharma.com </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-96958c1c1275e460bebf23cdf143ad79
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lysodren Package Leaflet for language en"
Description: "ePI document Bundle for lysodren Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-96958c1c1275e460bebf23cdf143ad79"
* entry[0].resource = composition-en-96958c1c1275e460bebf23cdf143ad79

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp96958c1c1275e460bebf23cdf143ad79"
* entry[=].resource = mp96958c1c1275e460bebf23cdf143ad79
                            
                    
Instance: bundlepackageleaflet-da-96958c1c1275e460bebf23cdf143ad79
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lysodren Package Leaflet for language da"
Description: "ePI document Bundle for lysodren Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-96958c1c1275e460bebf23cdf143ad79"
* entry[0].resource = composition-da-96958c1c1275e460bebf23cdf143ad79

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp96958c1c1275e460bebf23cdf143ad79"
* entry[=].resource = mp96958c1c1275e460bebf23cdf143ad79
                            
                    



Instance: mp96958c1c1275e460bebf23cdf143ad79
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Lysodren 500 mg tablets"
Description: "Lysodren 500 mg tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/04/273/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Lysodren 500 mg tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 96958c1c1275e460bebf23cdf143ad79ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "lysodren"

* status = #current
* mode = #working

* title = "List of all ePIs associated with lysodren"

* subject = Reference(mp96958c1c1275e460bebf23cdf143ad79)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#lysodren "lysodren"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-96958c1c1275e460bebf23cdf143ad79) // lysodren en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-96958c1c1275e460bebf23cdf143ad79) // lysodren da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-96958c1c1275e460bebf23cdf143ad79
InstanceOf: List

* insert 96958c1c1275e460bebf23cdf143ad79ListRuleset
    